| Outcome Measures: |
Primary: Effect of dapagliflozin relative to glimepiride at 24 weeks of treatment period regarding central systolic blood pressure, To assess the effect of dapagliflozin relative to glimepiride at 24 weeks of treatment period in subjects with T2DM, with inadequate glycemic control regarding central systolic blood pressure estimated by applanation tonometry, 24 weeks | Secondary: Effect of dapagliflozin relative to glimepiride at 24 weeks regarding central systolic/diastolic blood pressure, To assess the effect of dapagliflozin relative to glimepiride at 24 weeks of treatment period in subjects with T2DM, with inadequate glycemic control regarding central systolic/diastolic blood pressure estimated by applanation tonometry., 24 weeks|Effect of dapagliflozin relative to glimepiride at 24 weeks regarding central pulse pressure, To assess the effect of dapagliflozin relative to glimepiride at 24 weeks of treatment period in subjects with T2DM, with inadequate glycemic control regarding central pulse pressure estimated by applanation tonometry., 24 weeks|Effect of dapagliflozin relative to glimepiride at 24 weeks of treatment with inadequate glycemic control regarding 24 hours ambulatory systolic/diastolic blood pressure, To assess the effect of dapagliflozin relative to glimepiride at 24 weeks of treatment period in subjects with T2DM, with inadequate glycemic control regarding 24 hours ambulatory systolic/diastolic blood pressure., 24 weeks|Type and number of Adverse events in patienteSafety and tolerability of dapagliflozin relative to glimepiride., Type and number of Adverse events to assess the safety and tolerability of dapagliflozin relative to glimepiride., 28 weeks|Effect of dapagliflozin relative to glimepiride at 24 weeks with inadequate glycemic control regarding augmentation pressure, To assess the effect of dapagliflozin relative to glimepiride at 24 weeks of treatment period in subjects with T2DM, with inadequate glycemic control regarding augmentation pressure estimated by applanation tonometry., 24 weeks|Effect of dapagliflozin relative to glimepiride at 24 weeks with inadequate glycemic control regarding augmentation index, o assess the effect of dapagliflozin relative to glimepiride at 24 weeks of treatment period in subjects with T2DM, with inadequate glycemic control regarding augmentation index estimated by applanation tonometry., 24 weeks
|
